The chemotherapy drugs of one out of every two patients receiving chemotherapy treatment in Turkey are prepared in the systems produced by Oncosem. The company, which will use all of the income from the capital increase of the public offering in the financing of new investments, exports its high technology products to more than 30 countries today.
As the sector leader in Turkey in the production of chemotherapy drug preparation systems, Oncosem Onkoloji Sistemleri Sanayi ve Ticaret A.Ş. being offered to the public. With 26 years of experience in the industry, the company specializes in the production of equipment used in cancer diagnosis and treatment, semi-finished components and medical devices, diagnostic products and protective equipment.
EXPORTS TO MORE THAN 30 COUNTRIES
Currently, chemotherapy drugs for one out of every two patients receiving chemotherapy treatment in Turkey are prepared in the systems produced by Oncosem. Finally, at the very beginning of the COVID-19 pandemic, the company produced antibody and antigen rapid test kits with completely domestic facilities and succeeded in exporting these products to more than 20 countries. The products produced by the company with high technology, including oncology products, are exported to more than 30 countries today.
IPO proceeds will be used for new investments
The application to the Capital Markets Board for the public offering of Oncosem was approved in its bulletin dated December 15, 2022. In the public offering carried out by Info Investment, the issued capital of the company is increased from 19 million 900 thousand TL to 23 million 850 thousand TL. 13 percent of the revenue targeted to be obtained from the public offering will be used to finance investments such as high-tech devices, technology transfer, clean room and waste systems in Germany, England and other foreign markets.
WILL BUILD A NEW FACTORY WITH 36 PERCENT
36 percent of the public offering income will be used in the investment of the new production factory planned to be established. While 28 percent of the said income is planned within the scope of machinery and equipment investments to increase production capacity, the remaining 23 percent of the supply income will be allocated for financing the working capital requirement.
Thanks to the system established in the oncology centers of 50 private and public health institutions in 30 countries and Turkey, with the benefits it provides to both healthcare professionals and patients, Oncosem, which provides chemotherapy support to one out of two patients, will carry this success story it wrote in Turkey to the global arena with the public offering.
SHARES ARE PUBLIC OFFERED AT 17.50 TL
In the public offering, which will be held with the ‘equal distribution’ method, 2 million nominal shares belonging to Oncosem Chairman of the Board Erol Çelik will also be subject to sale. In the public offering, where the book-building date was 28-29 December 2022, the price per share was determined as 17.50 TL.
EROL CELIK OWNS 90 PERCENT OF SHARES
EC Investments Holding, operating under the roof of Lydia Investment Holding, and Bulls Venture Capital Investment Trust are among the shareholders of Oncosem, whose Chairman of the Board is Erol Çelik, who is also the founder of the company. Oncosem, 90 percent of which is owned by Erol Celik, has a 5 percent share of EC Investments Holding; The remaining 5 percent share belongs to Bulls Private Equity Investment Trust…
Lydia Investment Holding, with its mission to add value to the country’s economy, operates in many different sectors, especially real estate, media, micro-mobility, health and renewable energy. The Holding invests in entrepreneurial companies in this field. Bulls Venture Capital Investment Trust, which puts the concept of ‘sustainability’ at the center of its investment policy, has investments in technology, micro-mobility, sports, sustainable innovative energy, health and health technologies.